investors got hung up on a comment made by Silviu that went along the lines of 'cash on hand is sufficient for approx 2 years burn' ... thinking that comment was taking into account sales and potential partnerships etc ... when in fact, he doesn't have a crystal ball and can't predict top line revenue, or partnerships right now... so if sales take off, and/or we get a partnership .. we won't need any further traditional capital raises... a partnership for instance would inject capital as part of the partnership... look at what happened with Cephalon and Mesoblast over a decade ago for an idea of what could happen in that space.
GG has also stopped buying .. hit kitty is full and he has now announced his position on the Board (very interesting)... so the significant buying pressure (smart money) that was buying at any given price .. driving the price to c. $3.30 and happy to soak up any shares available... obviously had a number in mind, and a limited time frame for him to get those shares... he knows how much Mesoblast is worth, and he has expressed his views now for the first time ... those who haven't read his quotes about why he invested in Mesoblast... should read it carefully.
Uncertainty on pricing and potential delays in launch... those concerned that US$300k was where we were going to land... analysts expected US$700-$800k... cold feet.
Now call it dumb money selling since .... driving the price down due to the above factors... its now pretty clear, launch is in March 2025.. pricing is double what analysts initially predicated and five times higher than what some feared... now this is all for our first product, small indication... adult is x3 or x4 the size... thats low hanging fruit... Silviu might not have a crystal ball, but analysts have excel, and can drag formulas with assumptions and growth factors now the key assumption of pricing can be set, and its much higher than what they expected ... and those cell column widths need to be expanded a bit wider to fit in all the zeros.
goodluck all
- Forums
- ASX - By Stock
- MSB
- Ann: Ryoncil Pricing Set and Available This Quarter
MSB
mesoblast limited
Add to My Watchlist
2.22%
!
$1.61

Ann: Ryoncil Pricing Set and Available This Quarter, page-37
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$1.61 |
Change
0.035(2.22%) |
Mkt cap ! $2.057B |
Open | High | Low | Value | Volume |
$1.60 | $1.63 | $1.58 | $6.778M | 4.238M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 2342 | $1.61 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.62 | 40395 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 2342 | 1.610 |
2 | 16350 | 1.605 |
7 | 96771 | 1.600 |
2 | 33138 | 1.595 |
4 | 54052 | 1.590 |
Price($) | Vol. | No. |
---|---|---|
1.615 | 40395 | 3 |
1.620 | 29739 | 3 |
1.625 | 35811 | 5 |
1.630 | 32834 | 3 |
1.635 | 21872 | 1 |
Last trade - 16.10pm 25/06/2025 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
The Watchlist
PTX
PRESCIENT THERAPEUTICS LIMITED
James McDonnell, CEO
James McDonnell
CEO
SPONSORED BY The Market Online